🔗 Visit the ClinicalTrials.gov page for NCT01132911
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. | Proc Natl Acad Sci U S A | 2003 | 3.30 |
| 2 | Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. | Clin Cancer Res | 2004 | 2.23 |
| 3 | SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. | Apoptosis | 2007 | 1.30 |
| 4 | Unfolded protein response to autophagy as a promising druggable target for anticancer therapy. | Ann N Y Acad Sci | 2012 | 1.21 |
| 5 | A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma. | Front Oncol | 2013 | 0.95 |
| 6 | Targeting Histone Deacetylases in Diseases: Where Are We? | Antioxid Redox Signal | 2014 | 0.88 |
| 7 | Advances in paediatric cancer treatment. | Transl Pediatr | 2014 | 0.76 |